Andrew T. Parsa, MD, PhD, from the University of California, San Francisco, describes the administration of the prophage G-200 for patients with recurrent glioblastoma multiforme.
Andrew T. Parsa, MD, PhD
Advertisement
Articles by Andrew T. Parsa, MD, PhD
Andrew T. Parsa MD, PhD, from the University of California, San Francisco, describes the design of a trial analyzing prophage G-200 vaccine for recurrent glioblastoma multiforme.
Advertisement
Latest Updated Articles
Dr. Parsa on a Trial Analyzing G-200 for GlioblastomaPublished: July 2nd 2013 | Updated:
Dr. Parsa on the Administration of the G-200 Vaccine in GBMPublished: August 21st 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5